File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1517/14728222.2012.662958
- Scopus: eid_2-s2.0-84863298936
- PMID: 22335485
- WOS: WOS:000301456700002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: An update on targeting Hippo-YAP signaling in liver cancer
Title | An update on targeting Hippo-YAP signaling in liver cancer |
---|---|
Authors | |
Keywords | Hippo pathway Liver cancer Oncogene YAP signaling |
Issue Date | 2012 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett |
Citation | Expert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 How to Cite? |
Abstract | Hepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/173030 |
ISSN | 2023 Impact Factor: 4.6 2023 SCImago Journal Rankings: 1.423 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, AM | en_US |
dc.contributor.author | Xu, Z | en_US |
dc.contributor.author | Luk, JM | en_US |
dc.date.accessioned | 2012-10-30T06:26:40Z | - |
dc.date.available | 2012-10-30T06:26:40Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Expert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 | en_US |
dc.identifier.issn | 1472-8222 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173030 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett | en_US |
dc.relation.ispartof | Expert Opinion on Therapeutic Targets | en_US |
dc.subject | Hippo pathway | - |
dc.subject | Liver cancer | - |
dc.subject | Oncogene | - |
dc.subject | YAP signaling | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Carcinoma, Hepatocellular - Metabolism | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Intracellular Signaling Peptides And Proteins - Metabolism | en_US |
dc.subject.mesh | Liver Neoplasms - Metabolism | en_US |
dc.subject.mesh | Nuclear Proteins - Metabolism | en_US |
dc.subject.mesh | Protein-Serine-Threonine Kinases - Metabolism | en_US |
dc.subject.mesh | Signal Transduction | en_US |
dc.subject.mesh | Transcription Factors - Metabolism | en_US |
dc.title | An update on targeting Hippo-YAP signaling in liver cancer | en_US |
dc.type | Article | en_US |
dc.identifier.email | Luk, JM: jmluk@hkucc.hku.hk | en_US |
dc.identifier.authority | Luk, JM=rp00349 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1517/14728222.2012.662958 | en_US |
dc.identifier.pmid | 22335485 | - |
dc.identifier.scopus | eid_2-s2.0-84863298936 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84863298936&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 243 | en_US |
dc.identifier.epage | 247 | en_US |
dc.identifier.isi | WOS:000301456700002 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Liu, AM=55276245300 | en_US |
dc.identifier.scopusauthorid | Xu, Z=55276228500 | en_US |
dc.identifier.scopusauthorid | Luk, JM=7006777791 | en_US |
dc.identifier.issnl | 1472-8222 | - |